UsAgainstAlzheimer’s Launches 2024 Brain Health Academy
April 16, 2024 10:48 ET
|
UsAgainstAlzheimer's
WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s today announced the return of its Brain Health Academy, scheduled to begin on May 9, 2024. First launched in 2022, the Academy...
Congress Passes Bills Making Major Investments in Alzheimer’s
March 23, 2024 10:15 ET
|
UsAgainstAlzheimer's
Congress passes major investments in the fight against Alzheimer’s.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
March 11, 2024 08:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s
March 08, 2024 07:55 ET
|
UsAgainstAlzheimer's
WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly, announced today that the Food and Drug Administration (FDA) will convene an advisory committee to consider the...
Global Neurological Biomarkers Market Analysis Report 2024-2030 - CAGR of 12.8% - Increased Funding For R&D in Biomarkers to Boost Development of New Drugs
January 24, 2024 05:40 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism),...
For people living with dementia, support changes everything. The Alzheimer Society connects Albertans to dementia-friendly support, knowledge, and community.
January 02, 2024 13:17 ET
|
Alzheimer Society of Alberta and NWT
Edmonton, Jan. 02, 2024 (GLOBE NEWSWIRE) -- A diagnosis of dementia is not easy. During National Alzheimer’s Awareness Month in January, the ALZHEIMER SOCIETY OF ALBERTA AND NORTHWEST TERRITORIES...
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
December 04, 2023 07:09 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Neurological Biomarkers Research Report 2023: A Global $18.75 Billion Market by 2030 with Pipeline Analysis of Alzheimer's, Parkinson's, Multiple Sclerosis, & Autism Spectrum Disorder
November 14, 2023 05:28 ET
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type,...
Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults
October 30, 2023 08:30 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Phase 1a Clinical Data Presented at Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development
Allyx Therapeutics to Present Phase 1 Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer's Disease Meeting
October 19, 2023 16:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics presents Phase 1 ALX-001 data at CTAD. ALX-001 is a small molecule with unique mechanism at mGluR5 to protect and preserve synapses.